ArticleCureus2025
Intractable Vomiting as an Initial and Evasive Presentation of Neuromyelitis Optica Spectrum Disorder.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon autoimmune neurological condition that is rarely associated with vomiting as the only initial symptom. We report a 67-year-old Caribbean female who was admitted to the general medicine ward with intractable vomiting for about two weeks. Her condition two weeks later progressed to brainstem syndrome, progressive dysphagia, and slurred speech. A month from admission, she developed quadriparesis, symptoms initially suggestive of a stroke. The underlying neurological diagnosis remained unclear for some time. Her initial symptoms were attributed to viral gastroenteritis, later with gastroscopy to esophagitis and subsequently to a possible stroke, which brain CT and MRI ruled out. However, a brain MRI with contrast revealed longitudinal and extensive hyperintense T2 changes in the brainstem, including the area postrema (lower medulla) and the cervical region. Ultimately, after more than a month of her admission, she was diagnosed with NMOSD, confirmed by the presence of aquaporin-4 antibodies in the cerebrospinal fluid via lumbar puncture. She received high-dose corticosteroid therapy and plasma exchange as acute treatment, followed by maintenance with mycophenolate. This led to improvements in her speech and swallowing; however, the improvement in her muscle weakness was not that prominent. After a long hospital admission, a patient was transferred to a neurorehabilitation centre to support recovery and enhance muscle strength, along with immunosuppressive treatment. During her extended hospital stay, the patient required nasogastric feeding, and her course was complicated by recurrent chest and urinary tract infections. This case highlights the atypical presentation and diagnostic challenges of NMOSD. We hope this report will help clinicians consider NMOSD earlier in similar clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.